Helix Biotech, Inc.

👀 Silicon in Lipid Nanoparticles??? 👀 Penn Engineers from the Michael J Mitchell lab have incorporated siloxane composites—compounds known for their stability and low toxicity—into lipid nanoparticles (LNPs) to target specific tissues. These compounds are already used in "medical devices, cosmetics and drug delivery." These newly engineered SiLNPs achieved enhanced mRNA delivery to specific organs, including the liver, lungs, and spleen, overcoming a major challenge of conventional #LNP, which typically accumulate in the liver. The insights provided in this study highlight how small changes in lipid chemistry can dramatically improve targeted #mRNA delivery. Read the Nature Nanotechnology Article Below 👇 https://lnkd.in/dsW2nh8N

I’ve had the good fortune to chat individually with Sanofi’s Sumit Luthra, Hopewell Therapeutics, Inc.’ Kate Zhang, and BioNTech SE’s Professor Ben Muir, and given how fantastic each of those individual conversations were, I can’t wait to see the magic that will happen when I bring them all together for my next Advancing RNA Live panel discussion. There are a lot of scientific and technical advancements we can celebrate in the LNP space since the pandemic. However, as we also know, there remain some big hurdles to achieving targeted therapeutic delivery using LNPs. We’ll be unpacking some of the latest “breaking” scientific advancements and improvements we’ve made in the R&D and CMC spaces, and how we’ll incrementally move our mRNA/RNA-LNP products beyond the liver. We’d love to have you join in on the fun on November 6 at 10 AM ET—register here! 

Join us! In this final Advancing RNA Live discussion of 2024, we sit down with three LNP experts to parse out the current opportunities and unknowns facing the development of next-generation LNPs. Registration is free thanks to the support of Helix Biotech, Inc. https://lnkd.in/eBxgZBgY

💥 Helix Biotech is heading to Salt Lake City, Utah for AAPS 2024 #PharmSci360! 💥 We know conferences are a great opportunity to connect, and we’re no exception! We love engaging with researchers, learning about their projects, and exploring how we can support them. Here are just a few of the ways we can help: 𝐋𝐍𝐏 𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬: Tailored lipid nanoparticle formulations to optimize drug delivery for your specific therapeutic needs. 𝐦𝐑𝐍𝐀 𝐒𝐲𝐧𝐭𝐡𝐞𝐬𝐢𝐬: High-quality, custom mRNA synthesis to support gene therapy, vaccine development, and other cutting-edge research. 𝐋𝐍𝐏 𝐌𝐟𝐠 𝐄𝐪𝐮𝐢𝐩𝐦𝐞𝐧𝐭: State-of-the-art systems for efficient and scalable nanoparticle production. 𝐆𝐌𝐏 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠: Highest standards of quality in the production of clinical-grade materials. 🗓 Come visit us at booth #1204 and let’s explore how we can support your formulation and drug development efforts! See you there! #AAPS #LNP #RNA #SaltLakeCity #HelixBiotech

Join us! In this 💥 final Advancing RNA Live discussion of 2024, we sit down with three LNP experts to parse out the current opportunities and unknowns facing the 🔬development of next-generation LNPs. Registration is free thanks to the support of Helix Biotech, Inc. Our host Anna Rose Welch along with industry experts will tackle unique LNP manufacturing hurdles, and unpack what's in the immediate future for RNA-LNP R&D and CMC. 🔗 Reserve Your Spot: https://lnkd.in/enw2fD94 📅 Wednesday, November 06, 2024 🕙 10:00 AM EDT | 1 HR #rna #lnp #cmc #RNAtherapeutics

Aerosolization of mRNA-LNPS 💥 A recent ACS Nano study by the Gaurav Sahay and Funai Microfluidics Groups highlights an incredible microfluidic aerosolization platform (MAP) that enhances mRNA delivery via inhalation. This platform not only preserves LNP integrity during nebulization but also significantly improves transfection efficiency, enabling targeted lung delivery without toxicity. We applaud the researchers for their contributions to the field and look forward to seeing how this technology can transform pulmonary gene therapy! Read the article below 👇 https://lnkd.in/eUPN9Hrp #LipidNanoparticles #mRNA #Aerosolization #HelixBiotech

Helix Biotech Fall mRNA Sale! 20% off our available in-stock mRNA, including: eGFP, FLuc, mCherry, EPO, Cas9, and CRE. Fall sale ends September 30th. Click the link below! https://wix.to/YxgZfBC #mRNA

💥 Exciting research in LNP cancer therapy 💥 Researchers from the Universidade Federal de Minas Gerais successfully developed LNPs for the targeted delivery of TRAIL mRNA, showing promising results in inhibiting colon cancer progression. TRAIL, or Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, is an innate immune cytokine that induces apoptosis specifically in tumor cells by binding to death receptors (DR4 and DR5) on their surface. It is expressed in various immune cells, including lymphocytes and natural killer cells, and plays a crucial role in suppressing tumor initiation and metastasis. TRAIL has garnered significant interest as a potential targeted therapy for cancer due to its ability to selectively trigger cell death in cancerous cells while sparing normal cells. Read the article below 👇 https://lnkd.in/gdzvVP7Y Visit our website for RNA synthesis and LNP development & manufacturing www.helixbiotech.com #mRNA #LNP #lipidnanoparticles #cancer #helixbiotech

🌟 Exciting Recognition for Helix Biotech in Latest JoVE Article! 🌟 We are thrilled to announce that Helix Biotech's Nova™ Benchtop system was acknowledged in a recently published JoVE article by Robert (Bob) Prud'homme and his team at Princeton University. The study, "Synthesizing Lipid Nanoparticles by Turbulent Flow in Confined Impinging Jet Mixers," demonstrates the advantages of this mixing principle over alternative mixing strategies, such as microfluidics and hand pipetting. Key highlights include: 🔬 Efficient LNP Synthesis using Impingement Jet Mixers and MIVMs, demonstrating rapid, scalable production of uniform nanoparticles. ⚙️ High Encapsulation Efficiency essential for nucleic acid therapeutics. 🌊 Impact of Reynolds Number on mixing efficiency, ensuring uniform particle size and polydispersity. 🏭 Scalability for GMP Production, supporting large-scale manufacturing, as seen in FDA-approved COVID-19 vaccines. This publication underscores the advantages of turbulent mixing over microfluidic approaches, particularly in scalability and process optimization. We are proud to contribute to such innovative research and continue driving impactful collaborations with our Nova™ platform. Read our blog post here: https://lnkd.in/eZjNFT4z Read the full article here: https://lnkd.in/ea9FtqbV #LipidNanoparticles #TurbulentFlow #IJM #HelixBiotech #GMP #LNPs #Nova